Search

Your search keyword '"M. Robles Díaz"' showing total 4 results
Start Over Author "M. Robles Díaz" Topic medicine
4 results on '"M. Robles Díaz"'

1. Clinical Characteristics and Outcome of Drug‐Induced Liver Injury in the Older Patients: From the Young‐Old to the Oldest‐Old

Author

Rianne A. Weersink, Ismael Alvarez‐Alvarez, Inmaculada Medina‐Cáliz, Judith Sanabria‐Cabrera, Mercedes Robles‐Díaz, Aida Ortega‐Alonso, Miren García‐Cortés, Elvira Bonilla, Hao Niu, German Soriano, Miguel Jimenez‐Perez, Hacibe Hallal, Sonia Blanco, Neil Kaplowitz, M. Isabel Lucena, Raúl J. Andrade, R.J. Andrade, M.I. Lucena, C. Stephens, M. García Cortés, M. Robles Díaz, A. Ortega Alonso, J. Pinazo, B. García Muñoz, R. Alcántara, A. Hernández, M.D. García‐Escaño, I. Medina‐Cáliz, J. Sanabria‐Cabrera, I. Alvarez‐Alvarez, E. Bonilla, H. Niu, D. Di‐Zeo, E. Del Campo, M. Jiménez Pérez, R. González Grande, S. López Ortega, I. Santaella, A. Ocaña, P. Palomino, M.C. Fernández, A. Porcel, M. Casado, M. González Sánchez, M. Romero‐Gómez, R. Millán‐Domínguez, B. Fombuena, R. Gallego, J. Ampuero, J.A. del Campo, R. Calle‐Sanz, L. Rojas, A. Rojas, A. Gil Gómez, E. Vilar, G. Soriano, C. Guarner, E.M. Román, M.A. Quijada Manuitt, R.M. Antonijoan Arbos, M. Farré, E. Montané, A.L. Arellano, A.M. Barriocanal, Y. Sanz, R.M. Morillas, M. Sala, H. Masnou Ridaura, J. Sánchez Delgado, M. Vergara Gómez, H. Hallal, E. García Oltra, J.C. Titos Arcos, A. Pérez Martínez, C. Sánchez Cobarro, J.M. Egea Caparrós, A. Castiella, J. Arenas, M.I. Gomez Osua, A. Gómez García, F.J. Esandi, S. Blanco, P. Martínez Odriozola, J. Crespo, P. Iruzubieta, J. Cabezas, A. Giráldez Gallego, E. del P. Rodríguez Seguel, M. Cuaresma, M. Prieto, I. Conde Amiel, M. Berenguer, M. García‐Eliz, J.M. Moreno, P. Martínez‐Rodenas, M. Garrido, C. Oliva, E. Gómez Domínguez, L. Cabrera, L. Cuevas, M. Bruguera, P. Gines, S. Lens, J.C. García, Z. Mariño, M. Hernández Guerra, M. Moreno San Fiel, C. Boada Fernández del Campo, J. Fuentes Olmo, E.M. Fernández Bonilla, F. Jorquera, and J. González Gallego

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Hígado - Enfermedades, Comorbidity, elderly, Severity of Illness Index, 030226 pharmacology & pharmacy, Culprit, oldest-old, Young Adult, 03 medical and health sciences, Liver disease, Sex Factors, 0302 clinical medicine, Levofloxacin, Internal medicine, medicine, Humans, Pharmacology (medical), Ticlopidine, Child, Aged, Aged, 80 and over, Pharmacology, Polypharmacy, business.industry, Age Factors, Odds ratio, Middle Aged, Jaundice, medicine.disease, mortality, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Spain, 030220 oncology & carcinogenesis, comorbitity, Female, Chemical and Drug Induced Liver Injury, medicine.symptom, business, drug-induced liver injury, Cholestatic, medicine.drug
Abstract

Old patients with hepatotoxicity have been scarcely studied in idiosyncratic drug-induced liver injury (DILI) cohorts. We sought for the distinctive characteristics of DILI in older patients across age groups. A total of 882 DILI patients included in the Spanish DILI Registry (33% ≥65 years) were categorized according to age: “young” (

Published
2020
Full Text
View/download PDF

2. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Simon Pape, Romée J.A.L.M. Snijders, Tom J.G. Gevers, Oliver Chazouilleres, George N. Dalekos, Gideon M. Hirschfield, Marco Lenzi, Michael Trauner, Michael P. Manns, John M. Vierling, Aldo J. Montano-Loza, Ansgar W. Lohse, Christoph Schramm, Joost P.H. Drenth, Michael A. Heneghan, P. Almasio, F. Alvarez, R. Andrade, C. Arikan, D. Assis, E. Bardou-Jacquet, M. Biewenga, E. Cancado, N. Cazzagon, O. Chazouillères, G. Colloredo, M. Cuarterolo, G. Dalekos, D. Debray, M. Robles-Díaz, J. Drenth, J. Dyson, C. Efe, B. Engel, S. Ferri, R. Fontana, N. Gatselis, A. Gerussi, E. Halilbasic, N. Halliday, M. Heneghan, G. Hirschfield, B. van Hoek, M. Hørby Jørgensen, G. Indolfini, R. Iorio, S. Jeong, D. Jones, D. Kelly, N. Kerkar, F. Lacaille, C. Lammert, B. Leggett, M. Lenzi, C. Levy, R. Liberal, A. Lleo, A. Lohse, S. Ines Lopez, E. de Martin, V. McLin, G. Mieli-Vergani, P. Milkiewicz, N. Mohan, L. Muratori, G. Nebbia, C. van Nieuwkerk, Y. Oo, A. Ortega, A. Páres, T. Pop, D. Pratt, T. Purnak, G. Ranucci, S. Rushbrook, C. Schramm, A. Stättermayer, M. Swain, A. Tanaka, R. Taubert, D. Terrabuio, B. Terziroli, M. Trauner, P. Valentino, F. van den Brand, A. Villamil, S. Wahlin, H. Ytting, K. Zachou, M. Zeniya, Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Pape, S., Snijders R.J., Gevers, T.J., Chazouilleres, O., Dalekos, G.N., Hirschfield, G.M., Lenzi, M., Trauner, M., Manns, M.P., Vierling, J.M., Montano Loza, A.J., Lohse, A.W., Schramm, C., Drenth, J.P., Heneghan, M.A., International Autoimmune Hepatitis Group (IAIHG), School of Medicine, Gastroenterology and hepatology, AII - Infectious diseases, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
autoimmune hepatitis, Hepatology, endpoints, endpoint, insufficient response, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], remission, non-response, complete biochemical response, intolerance, Autoimmune hepatitis, Complete biochemical response, Endpoints, Insufficient response, Intolerance, Non-response, Remission, Medicine, autoimmune hepatiti
Abstract

Background and aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: a systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: the consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term 'complete biochemical response' defined as 'normalization of serum transaminases and IgG below the upper limit of normal' be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ', YAEL Foundation

Published
2022
Full Text
View/download PDF

3. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry

Author

Hao Niu, José M. González, R. Quiles, S. Lorenzo, Antonio Madejón, Sabela Lens, J. Pinazo, Eduardo Vilar, F.J. Esandi, A.M. Barriocanal, L. Cuevas, Raúl J. Andrade, G. Soriano, P. Martínez Odriozola, E. del P. Rodríguez Seguel, J.C. Titos Arcos, Zoe Mariño, J.A. Del Campo, E. García Oltra, J. García Samaniego, Isabel Conde, C. Boada Fernández del Campo, Germán Soriano, J.M. Moreno Sanfiel, A. de Juan Gómez, G. Pelaez, J.M. Pérez-Moreno, José Luis Montero, Rosa Maria Morillas, A. Hernández, S. Blanco, A. Ocaña, Maria Sala, Judith Sanabria-Cabrera, I. Santaella, J. Sánchez Delgado, H. Hallal, J. Miguel Moreno-Sanfiel, A. Gómez García, J.M. Egea Caparrós, M. Fernández Gil, C. Stephens, R. Calle-Sanz, Eva Román, A. Gila, E. Gómez Domínguez, B. Fombuena, Álvaro Giráldez, A. Ortega-Alonso, Ángela Rojas, A. Papineau, Pedro Otazua, Rocio Sanjuan-Jimenez, R. Millán-Domínguez, María Cuaresma, I. Álvarez-Álvarez, Joaquín Cabezas, José María Moreno-Planas, J.L. Cabriada, A. Giráldez Gallego, Martín Prieto, J. Sanabria-Cabrera, Inmaculada Medina-Caliz, E. Zapata, E. Montané, Joaquín Arenas, M. Jiménez Pérez, P. Martínez-Rodenas, Miren García-Cortés, B. García Muñoz, M. González Sánchez, Javier Ampuero, M.C. Fernandez, E. del Campo, Carlos Guarner, Miguel Jiménez-Pérez, M. Isabel Lucena, M. Prieto, Jose Luis Calleja, P. Rendon, A. Gil Gómez, E.M. Fernández Bonilla, I. Conde Amiel, Javier Crespo, Ana Lucía Arellano, J.R. Molés, César Fernández, Miguel A. Casado, M. Vergara Gómez, M. García Cortes, P. Palomino, Aida Ortega-Alonso, M. Carmen Fernández, Manuel Romero-Gómez, M. Romero-Gómez, J. González Gallego, Elvira Bonilla, A. Castiella, María García-Eliz, Marta Tejedor, M.A. Quijada Manuitt, J.M. Moreno, M.I. Lucena, J. Fuentes Olmo, E.M. Román, Agustin Castiella, A. Garayoa, I. Medina-Cáliz, Mahmoud Slim, M. Hernandez Guerra, R. Alcantara, C. Sánchez Cobarro, Marina Berenguer, J.L. Martínez Porras, Pere Ginès, J.C. García, A. Porcel, Neil Kaplowitz, Ismael Alvarez-Alvarez, D. Di Zeo, JM Salmerón, R.J. Andrade, A. González-Jiménez, A. Pérez Martínez, C. Lara, H. Masnou Ridaura, Miquel Bruguera, R. González Grande, A. Cueto, M. Villanueva, Marta Casado, J. Primo, S. López Ortega, Paula Iruzubieta, M. Carrascosa, Rocío Gallego, M. Garrido, Liliana Rendón Rojas, S. Sánchez Campos, M. Robles-Díaz, R.M. Antonijoan Arbos, Mercedes Robles-Díaz, F. Jorquera, C. Oliva, Camilla Stephens, M.D. García Escaño, M. de la Mata, Yolanda Sanz, R. González Ferrer, Magí Farré, Rocío González-Grande, Instituto de Salud Carlos III, European Commission, Agencia Española de Medicamentos y Productos Sanitarios, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), and Junta de Andalucía

Subjects
0301 basic medicine, Male, Epidemiology, Autoimmune hepatitis, Hepatitis, Liver disease, 0302 clinical medicine, Anti-Infective Agents, Liver Function Tests, Causative agents, Risk Factors, Risk of mortality, Registries, Outcome, Liver injury, Liver Diseases, Age Factors, Middle Aged, Prognosis, 030211 gastroenterology & hepatology, DILI, Female, Chemical and Drug Induced Liver Injury, medicine.medical_specialty, Liver-related death, DILI, Hepatotoxicity, causative agents, drug-induced autoimmune hepatitis, epidemiology, liver-related death, outcome, risk factors, therapy in DILI, Risk Assessment, 03 medical and health sciences, Internal medicine, medicine, Epidemiología, Humans, Aspartate Aminotransferases, Mortality, Drug-induced autoimmune hepatitis, Hepatology, business.industry, Platelet Count, Hepatotoxicity, Odds ratio, medicine.disease, Comorbidity, Liver Transplantation, Transplantation, 030104 developmental biology, Risk factors, Spain, Chronic Disease, business, Therapy in DILI
Abstract

[Background & Aims] Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period., [Methods] Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected., [Results] A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974–0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994–0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy’s law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%)., [Conclusions] AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management., [Lay summary] Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes., The present study has been supported by grants of Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional – FEDER (contract numbers: PI19/00883, PI16/01748, PI18/00901, PI18/01804, PI-0285-2016, PI-0274-2016, PI-0310-2018, PT17/0017/0020) and Agencia Española del Medicamento. CIBERehd and Plataforma ISCIII Ensayos Clinicos are funded by Instituto de Salud Carlos III. MRD holds a Joan Rodes (JR16/00015)/Acción B clinicos investigadores (B-0002-2019) and JSC a Rio Hortega (CM17/00243) research contract from ISCIII and Consejería de Salud de Andalucía.

Published
2021

4. Retransplant Due to Fulminant Hepatic Failure From Hepatitis E Virus: A Case Report

Author

R. González Grande, M. Robles Díaz, R.V. Olmedo Martín, R. Sanjuan Jiménez, J.M. Rodrigo López, M. Jiménez Pérez, and E Tenorio González

Subjects
Adult, Reoperation, medicine.medical_specialty, Cirrhosis, Blood transfusion, medicine.medical_treatment, 030230 surgery, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Fulminant hepatic failure, Hepatitis E virus, Internal medicine, medicine, Humans, Transplantation, Transmission (medicine), business.industry, Zoonosis, Liver failure, Liver Failure, Acute, medicine.disease, Hepatitis E, Liver Transplantation, Chronic infection, 030211 gastroenterology & hepatology, Surgery, Female, business
Abstract

Hepatitis E virus (HEV) usually causes self-limiting acute liver infections from fecal or oral transmission, though other routes of infection exist (vertical transmission, blood transfusion, zoonosis). It may give rise to fulminant hepatic failure in 1% of cases. Cases have recently been reported of chronic infection evolving to cirrhosis in immunosuppressed patients, such as those with a liver or kidney transplant. Nonetheless, development of acute liver failure in these patients is exceptional, with few cases published. We present a case of acute liver failure due to HEV in a liver transplant patient who required a liver retransplant 9 years after receiving the original transplant.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results